In the subgroup analysis of patients with HBV+ DLBCL, no significant differences in PFS or OS outcomes were observed between patients with MYC/BCL2 double-expression status in the chidamide and control groups (Figures 4A and 4B; OS: p = 0.747; PFS: p = 0.406). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.